RxDoctor Payments DataLook up a doctor →

Xuanha White, DO

Critical Care Medicine · San Diego, CANPI 1427346154

Payments from drug & device makers

$343,021in general payments, 2019–2025

Across 934 payments — averaging $367.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$112K
  • AstraZeneca$111K
  • Inspire Medical Systems, Inc.$60K
  • GSK$38K
  • Regeneron Healthcare Solutions, Inc.$7K
  • Pinnacle Biologics, Inc$3K
  • plus $12K from 48 others

What the payments were for

  • Consulting fees$68,75220%
  • Speaking & faculty fees$210,07461%
  • Travel & lodging$33,46310%
  • Food & beverage$28,3618%
  • Education$2,3541%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$343,021 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$694,729
Medicare patients
897
Services billed
5,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate14$192,141
Trelegy ElliptaFluticasone/Umeclidin/Vilanter210$190,258
Breztri AerosphereBudesonide/Glycopyr/Formoterol156$115,585
Breo ElliptaFluticasone/Vilanterol157$78,681
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr147$73,488
Dupixent PenDupilumab18$66,865
Dupixent SyringeDupilumab12$45,157
Stiolto RespimatTiotropium Br/Olodaterol Hcl62$41,408
Spiriva RespimatTiotropium Bromide47$30,483
Combivent RespimatIpratropium/Albuterol Sulfate20$18,321
SunosiSolriamfetol Hcl11$9,554
Pirfenidone14$9,364
Incruse ElliptaUmeclidinium Bromide17$7,402
Atrovent HfaIpratropium Bromide13$6,976
Albuterol Sulfate HfaAlbuterol Sulfate204$5,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$37,601$349,829531 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$746$282,352143 claims
AstraZenecaBreztri Aerosphere, Symbicort$110,725$118,618167 claims
Axsome Therapeutics, Inc.Sunosi$97$9,55411 claims
MerckDulera$87$4,71314 claims
Eisai Inc.Dayvigo$151$3,60511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.

Other critical care medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →